LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hamidi, Parinaz.
Languages: English
Types: Doctoral thesis
Subjects: RM

Classified by OpenAIRE into

mesheuropmc: biological phenomena, cell phenomena, and immunity, enzymes and coenzymes (carbohydrates)
Cancer is a new growth that arises from abnormal and uncontrolled division of cells that may go on to invade and destroy surrounding tissues. The eukaryotic cell cycle consists of a complex sequence of events that regulates cell division and responses to DNA damage. These processes rely upon several key enzymes, including the cyclin dependent kinases (CDKs), checkpoint kinases (Chk2) and poly(ADP-ribose)polymerase-l (PARP-1). CDKs are a family of protein kinases that control progression of the cell cycle, and are themselves regulated by a complex network of activating and inhibitory mechanisms. The vital importance of CDKs in regulating of the cell cycle, emphasise their importance as anti-cancer drug targets. CDKs inhibitors compete with the natural substrate ATP in a competitive manner. Hymenialdisine and kenpaullone have been identified as novel and potent CDK inhibitors both containing an unusual azepinone scaffold. Checkpoint kinase 2 (Chk2) is a novel target for anti-cancer drug design. The enzyme mediates cell proliferation in response to DNA damage by inducing cell cycle arrest, which facilitates the DNA repair pathways. Chk2 inhibition has been recognised as a potential target for the chemopotentiation of current anti-cancer treatments. Few Chk2 inhibitors are known, kenpaullone has been identified as a novel and selective ATP competitive Chk2 inhibitor (IC50 = 0.8 uM). Debromohymenialdisine (DBH) also containing an azepinone scaffold has also been reported to inhibit Chk2. Poly(ADP-ribose)polymerase-l (PARP-1) is activated in response to DNA damage, and inhibition can potentiate cancer chemotherapy and radiotherapy. A PARP-1 inhibitor in combination with a cytotoxic agent should enhance drug activity by blocking the repair capabilities of PARP-1 in cancer cells. Although many types of inhibitors have been identified for each of these three enzymes, compounds containing a seven-membered lactam ring have been identified as key inhibitors for CDKs/Chk2/PARP-l. This study is entered upon developing the synthesis for a series of novel inhibitors of these three enzymes containing the essential lactam pharmacophore in their structures. The compounds synthesised in this study were assessed by a number of biological assays showing moderate or good growth or catalytic inhibitory activity against CDKs and PARP-1 respectively, while assays against Chk2 showed no inhibition.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Brown, V. D., Phillips, R. A., and Gallie, B. L. 1999b. Cumulative effect o f phosphorylation o f pRB on regulation o f E2F activity. Mol. Cell. Biol. 19, 3246- 3256.
    • Buolamvvini, J. K. 2001. Cell cycle m olecular targets and drug discovery., Vol. 2001. [WWW].
    • Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvet, A. H., CananKokh, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., Li, J., Maegley, K., Newell, D. R., N otarianni, E., Stratford, I. J., Skalitzky, D. J., Thomas, H. D., Wang, L. Z., Webber, S. E., W illiams, K. J., and Curtin, N. J. 2004. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG 14361. J. Nat. Cancer Instit. 96, 56-67.
    • Chaturvedi, P., Eng, W. K., Zhu, Y., M attem , M. R., Mishra, R., Hurie, M. R., Zhang, X. L., Annan, R. S., Lu, Q., Faucette, L. F., Scott, G. F., Li, X. T., Carr, S. A., Johnson, R. K., W inkler, J. D., and Zhou, B. B. S. 1999. M ammalian Chk2 is a downstream effector o f the ATM -dependent DNA damage checkpoint pathway. Oncogene 18, 4047-4054.
    • Chehab, N. H., Malikzay, A., Appel, M., and Halazonetis, T. D. 2000. Chk2/hCdsl functions as a DNA damage checkpoint in G (l) by stabilizing p53. Genes Dev. 14, 278-288.
    • Cohen, P. 1999. The development and therapeutic potential o f protein kinase inhibitors. Curr. Opin. Chem. Biol. 3, 459-465.
    • Coleman, K. G., Lysikatos, J. P., and Yang, B. V. 1997. Chemical inhibitors o f cyclin dependent kinases. Annu. Rep. Med. Chem 32, 171-179.
    • Cooper, G. M. 2000. "The cell: A Molecular Approach," 2nd Ed. ASM press, U.S.A.
    • Crews, C. M., and Mohan, R. 2000. Small-molecule inhibitors o f the cell cycle. Curr. Opin. Chem. Biol. 4, 47-53.
    • Curman, D., Cinel, B., W illiams, D. E., Rundle, N., Block, W. D., Goodarzi, A. A., Hutchins, J. R., Clarke, P. R., Zhou, B. B., Lees-Miller, S. P., Andersen, R. J., and Roberge, M. 2001. Inhibition o f the G(2) DNA damage checkpoint and o f protein kinases Chkl and Chk2 by the marine sponge alkaloid debromohymenialdisine. J. Biol. Chem. 276, 17914-17919.
    • D'Amours, D., Desnoyers, S., D'Silva, I., and Poirier, G. G. 1999. Poly(ADP-ribosyl)ation reactions in the regulation o f nuclear functions. Biochem. J. 342, 249-268.
    • D'Silva, I., Pelletier, J. D., Lagueux, J., D 'Amours, D., Chaudhry, M. A., Weinfeld, M., Lees-Miller, S. P., and Poirier, G. G. 1999. Relative affinities o f poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. BBA-Prote in Struct. M. 1430, 119-126.
    • Davidovic, L., Vodenicharov, M., Affar, E. B., and Poirier, G. G. 2001. Importance o f poly(ADP-ribose) glycohydrolase in the control o f poly(ADP-ribose) metabolism. Exp. Cell Res. 268, 7-13.
    • Davies, T. G., Bentley, J., Arris, C. E., Boyle, F. T., Curtin, N. J., Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Hardcastle, I. R., Jewsbury, P., Johnson, L. N., Mesguiche, V., Newell, D. R., Noble, M. E. M., Tucker, J. A., Wang, L., and Whitfield, H. J. 2002. Structure-based design o f a potent purine-based cyclindependent kinase inhibitor. Nat. Struct. Biol. 9, 745-749.
    • De Azvedo, W. F., Leclerc, S., Meijer, L., Havilcek, L., Strand, M., and Kim, S. H. 1997. Inhibition o f cyclin-dependent kinases by purine analogues crystal structure o f human cdk2 complexed with Roscovitine. Eur. J. Biochem 243, 518-526.
    • Draetta, G., and Eckstein, J. 1997. Cdc25 protein phosphatases in cell proliferation. Biochim. Biophys. Acta-Rev. Cancer 1332, M53-M63.
    • Dreyer, M. K., Borcherding, D. R., Dum ont, J. A., Peet, N. P., Tsay, J. T., Wright, P. S., Bitonti, A. J., Shen, J., and Kim, S. H. 2001. Crystal structure o f human cyclindependent kinase 2 in com plex with the adenine-derived inhibitor H717. J. Med. Chem 44, 524-530.
    • Eldeiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. 1993. W afl, a Potential Mediator o f P53 Tumor Suppression. Cell 75, 817-825.
    • Elledge, S. J. 1996. Cell cycle checkpoints: Preventing an identity crisis. Science 274, 1664-1672.
    • Evans, T., Rosenthal, E. T., Youngblom, J., Distel, D., and Hunt, T. 1983. Cyclin: a protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 33, 389-396.
    • Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S. W., Fendrich, G., Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H., Zimmermann, J., Meyer, T., Caravatti, G., Furet, P., and Manley, P. W. 2002. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 93, 79-98.
    • Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J., and Lukas, J. 2001. The ATM-Chk2- Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847.
    • Ferraris, D. V., Li, J.-H., Kalish, V. J., and Zhang, J. 2002. Preparation o f benzazepinones, isoquinolinones and related compounds as inhibitors o f poly(ADP-ribose) polymerase (PARP) for the prevention and/or treatment o f _ _ _ . 221
    • Fischer, P. M., and Lane, D. P. 2000. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. Curr. Med. Chem. 7, 1213-1245.
    • Fisher, R. P., and M organ, D. O. 1994. A Novel Cyclin Associates with M ol5/C dk7 to Form the Cdk- A ctivating Kinase. Cell 78, 713-724.
    • Fry, D. W. 1999. Inhibition o f the epidermal growth factor receptor family o f tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors. Pharmacol. Ther. 82, 207-218.
    • Gaken, J. A., Tavassoli, M., Gan, S. U., Vallian, S., Giddings, I., Darling, D. C., GaleaLauri, J., Thom as, M. G., Abedi, H., Schreiber, V., M enissierdeM urcia, J., Collins, M. K. L., Shall, S., and Farzaneh, F. 1996. Efficient retroviral infection o f mammalian cells is blocked by inhibition o f poly(ADP-ribose) polymerase activity. J. Virol. 70, 3992-4000.
    • Garin, J., Melendez, E., M erchan, F. L., and Tejero, T. 1987. Pyrido [2,3-b] [1,5] Benzodiazepines - Synthesis and Reactivity Towards (Hetero) Aromatic Acid Halides. An. Quim. C-Org. Bioquim. 83, 52-54.
    • Garrett, M. D., and Fattaey, A. 1999. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 9, 104-111.
    • Cartel, A. L., Serfas, M. S., and Tyner, A. L. 1996. p21-Negative regulator o f the cell cycle. Proc. Soc. Exp. Biol. Med. 213, 138-146.
    • Giani, R. P., Borsa, M., Parini, E., and Tonon, G. C. 1985. A new facile synthesis o f 11- oxo-10,11-dihydro-5H- dibenzo [b,e][l ,4] diazepines. Synthesis, 550-552.
    • Gibson, A. E., Arris, C. E., Bentley, J., Boyle, F. T., Curtin, N. J., Davies, T. G., Endicott, J. A., Golding, B. T., Grant, S., Griffin, R. J., Jewsbury, P., Johnson, L. N., Mesguiche, V., Newell, D. R., Noble, M. E. M., Tucker, J. A., and W hitfield, H. J. 2002. Probing the ATP ribose-binding dom ain o f cyclin-dependent kinases 1 and 2 with 06-substituted guanine derivatives. J. Med. Chem. 45, 3381-3393.
    • Gill, G. N., and Lazar, C. S. 1981. Increased Phosphotyrosine Content and Inhibition o f Proliferation in Egf-Treated A431 Cells. Nature 293, 305-307.
    • Graves, P. R., Yu, L., Schwarz, J. K., Gales, J., Sausville, E. A., O'Connor, P. M., and Piwnica-W orms, H. 2000. The C hkl protein kinase and the Cdc25C regulatory pathways are targets o f the anticancer agent UCN-01. J . Biol. Chem. 275, 5600- 5605.
    • Gray, N., Detivaud, L., Doerig, C., and M eijer, L. 1999. ATP-site directed inhibitors o f cyclin-dependent kinases. Curr. Med. Chem. 6, 859-875.
    • Greenblatt, M. S., Bennett, W. P., H ollstein, M., and Harris, C. C. 1994. Mutations in the P53 Tumor-Suppressor Gene - Clues to Cancer Etiology and M olecular Pathogenesis. Cancer Res. 54, 4855-4878.
    • Greene, T. W., and Wuts, P. G. M. 1999. "Protective groups in organic synthesis," 3rd Ed. Wiley-Interscience.
    • Griffin, R. J., Pemberton, L. C., R hodes, D., Bleasdale, C., Bowman, K., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Newell, D. R., and Porteous, J. K. 1995. Novel potent inhibitors o f the DN A repair enzyme poly (ADP-ribose) polymerase (PARP). AntiCancer D rug Des. 10, 507-514.
    • Griffin, R. J., Srinivasan, S., Bow m an, K. J., Calvet, A. H., Curtin, N. J., Newell, D. R., Pemberton, L. C., and G olding, B. T. 1998. Resistance-modifying agents. Synthesis and biological properties o f quinazlinone inhibitors o f the DNA repair enzyme poly (ADP-ribose) polym erase (PARP). J. Med. Chem. 41, 5247-5256.
    • Grivas, S., and Olsson, K. 1985. An im proved synthesis o f 3,8-dim ethyl-3//-im idazo[4,5- /]quinoxalin-2-amine("M eIQx") and its 2 -14C-labelled analogue. Acta Chemica Scandinavica B 39, 31-34.
    • Gross, M. E., Zorbas, M. A., Danels, Y. J., Garcia, R., Gallick, G. E., Olive, M., Brattain, M. G., Boman, B. M., and Yeoman, L. C. 1991. Cellular Growth-Response to Epidermal Growth-Factor in Colon- Carcinom a Cells with an Am plified Epidermal Growth-Factor R eceptor Derived from a Familial Adenomatous Polyposis Patient. Cancer Res. 51, 1452-1459.
    • PhD Thesis, P Hamidi, 2006
    • Guo, M., and Hay, B. H. 1999. Cell proliferation and appoptosis. Curr. Opin. C ell Biol 11,754-752.
    • Hardcastle, I. R., Arris, C. E„ Bentley, J., Boyle, F. T., Chen, Y. H., Curtin, N. J„ Endicott, J. A., Gibson, A. E., Golding, B. T., Griffin, R. J., Jewsbury, P., Menyerol, J., M esguiche, V., Newell, D. R., Noble, M. E. M., Pratt, D. J., Wang, L. Z., and W hitfield, H. J. 2004. N-2-substituted O-6-cyclohexylmethylguanine derivatives: Potent inhibitors o f cyclin-dependent kinases 1 and 2. J. Med. Chem 47, 3710-3722.
    • Harley, C. B. 1991. Telomere loss: mitotic clock or genetic time bomb? Mutat. Res. 256, 271-282.
    • Harley, C. B., Futcher, A. B., and Grieder, C. W. 1990. Telomeres shorten during ageing o f human fibroblasts. Nature 345, 458-460.
    • Harper, J. W. 1997. Cyclin dependent kinase inhibitors. Cancer Surv. 29, 91-107.
    • Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. 1993. The p21 CDK-interacting protein CIP1 is a potent inhibitor o f G1 cyclin-dependent kinases. Cell 75, 805-816.
    • Harris, N. V., Smith, C., and Bowden, K. 1990. Antfolate and antibacterial activities o f 5- substituted 2, 4-diaminoquinazolines. J.Med.Chem. 33, 434-444.
    • Hartwell, L. 1992. Deffects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71, 543-546.
    • Hartwell, L. H., and Kastan, M. B. 1994. Cell-Cycle Control and Cancer. Science 266, 1821-1828.
    • Hatakeyama, K., Nemoto, Y., Ueda, K., and Hayaishi, O. 1986. Purification and Characterization o f Poly(Adp-Ribose) Glycohydrolase - Different Modes o f Action on Large and Small Poly(Adp-Ribose). J. Biol. Chem. 261, 4902-4911.
    • Hengst, L., and Reed, S. I. 1996. Translational control o f p27(kipl) accumulation during the cell cycle. Science 271, 1861-1864.
    • Hinterding, K., AlonsoDiaz, D., and Waldmann, H. 1998. Organic synthesis and biological signal transduction. Angew. Chem. Int. E d 37, 688-749.
    • Hiremath, S. P., Badami, P. S., and Purohoit, M. G. 1984. Synthesis of substituted 7,12- dihydroindolo[3,2-/>][ 1,4]benzodiazepin-5-(6//)-ones and 1,2,3,4,5,6- hexahydro[l,3]diazepino[5,6-£]indole-l,5-diones. Indian J. Chem, Section B: Organic Chemistry including M edicinal Chemistry 23B, 1058-1063.
    • Ho, A., and Dowdy, S. F. 2002. Regulation o f G (l) cell-cycle progression by oncogenes and tumor suppressor genes. Curr. Opin. Genet. Dev. 12,47-52.
    • Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., Niederberger, E., Tang, W. C., Eisenbrand, G., and Meijer, L. 1999. Indirubin, the active constituent o f a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. 1, 60- 67.
    • Hossel, R., nLecrec, S., Endicott, J. A., N obbel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., M arko, D., Niederberger, E., Tang, W., Eisenbrand, G., and Meijer, L. 1999. Indirubin, the active constituent o f a Chinese antileukemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol. 1, 60- 67.
    • Hunter, T. 1987. A 1001 Protem-Kinases. Cell 50, 823-829.
    • Jagtap, P., and Szabo, C. 2005. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. D rug Discov. 4, 421-440.
    • Jeffery, D. A., Springer, M „ King, D. S., and O'Shea, E. K. 2001. Multisite phosphorylation o f Pho4 by the cyclin-CDK Pho80-Pho85 is semi-processive with site preference.J. Mol. Biol 306, 997-1010.
    • Jeffrey, P. D., Ruso, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and Pavletich, N. P. 1995. M echanism o f Cdk Activation Revealed by the Structure o f a Cyclina-Cdk2 Complex. Nature 376, 313-320.
    • Johnson, D. G., and W alker, C. L. 1999. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39, 295-312.
    • Jorgensen, M. R., Olsen, C. A., Mellor, I. R., Usherwood, P. N. R., Witt, M., Franzyk, H., and Jaroszewski, J. W. 2005. The effects o f conformational constraints and steric bulk in the amino acid moiety o f philanthotoxins on AMPAR antagonism. J. Med. Chem 48, 56-70.
    • Kaldis, P., Sutton, A., and Solomon, M. J. 1996. The Cdk-activating kinase (CAK) from budding yeast. Cell 86, 553-564.
    • Kaneko, Y., Watanabe, N., M orisaki, H., Akita, H., Fujimoto, A., Tominaga, K., Terasawa, M., Tachibana, A., Ikeda, K., and Nakanishi, M. 1999. Cell cycledependent and ATM -independent expression o f human C hkl kinase. Oncogene 18, 3673-3681.
    • Kastan, M. B., and Bartek, J. 2004. Cell-cycle checkpoints and cancer. Nature 432, 316- 323.
    • Kastan, M. B., and Lim, D. S. 2000. The many substrates and functions o f ATM. Nat. Rev. Mol. Cell Biol. 1, 179-186.
    • Kastan, M. B., Zhan, Q. M., Eldeiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fom ace, A. J. 1992. A M ammalian-Cell Cycle Checkpoint Pathway Utilizing P53 and Gadd45 Is Defective in AtaxiaTelangiectasia. Cell 71, 587-597.
    • Kavanaugh, W. M., and Williams, L. T. 1996. "Signalling through receptor Tyrosine kinases: In Signal Transduction," Chapm an & Hall.
    • Kavvabe, T., Muslin, A. J., and Korsmeyer, S. J. 1997. HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature 385, 454-458.
    • Kickhoefer, V. A., Siva, A. C., Kedersha, N. L., Inman, E. M., Ruland, C., Streuli, M., and Rome, L. H. 1999. The 193-kD vault protein, VPARP, is a novel Poly(ADPribose) polymerase. J. Cell Biol. 146, 917-928.
    • Klein, M., and Boche, G. 1999. Regiospeciflc synthesis o f substituted nitrofluorenes with the Negishi coupling reaction as key step. Synthesis 7, 1246-1250.
    • Knockaert, M., Greengard, P., and M eijer, L. 2002. Pharmacological inhibitors of cyclindependent kinases. Trends Pharmacol. Sci. 23, 417-425.
    • Koh, J., Enders, G. H., B.D., D., and Harlow, E. 1995. Tumor-derived p l6 allels encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510.
    • Krolski, M. E., Renaldo, A. F., Rudisill, D. E., and Stille, J. K. 1988. Palladium-catalyzed coupling o f 2-bromoanilines with vinylannanes. A regiocontrolled synthesis o f substituted indoles. . J. Org. Chem. 53, 1170-1176.
    • Kropp, P. J., and Pienta, N. J. 1983. Photochemistry o f Alkyl-Halides .9. Geminal Dihalides. J. Org. Chem. 48, 2084-2090.
    • Kunick, C., Schultz, C., Lemcke, T., Zaharevitz, D. W.,Gussio, R., Jaluri, R. K., Sausville, E. A., Leost, M., and M eijer, L. 2000. 2-Substituted Paullones: CDK1/ cyclin C inhibiting property and in vitro antiproliferative activity. Bioorg. Med. Chem. Lett 10, 567-569.
    • LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., and Harlow, E. 1997. N ew functional activities for the p21 family o f CDK inhibitors. Genes Dev. 11, 847-862.
    • Lee, J. S., Collins, K. M., Brown, A. L., Lee, C. H., and Chung, J. H.2000.hC dslmediated phosphorylation o f BRCA1 regulates the DNA damage response. Nature 404, 201-204.
    • Lee, S. E., Mitchell, R. A., Cheng, A., and Hendrickson, E. A. 1997. Evidence for DNAPK-dependent and independent DNA double-strand break repair pathways in mammalian cells as a function o f the cell cycle. Mol. Cell. Biol. 17, 1425-1433.
    • Lieber, M., Smith, B., Szakal, A., Nelson-Rees, W., and Todaro, G. 1976. A continuous tumour-cell line from a human lung carcinoma with properties o f type II alveolar epithelial cells. Int. J. Cancer. 17, 62-70.
    • Liu, Q., Guntuku, S., Cui, X., M atsuoka, S., Cortez, D., Tamai, K., Luo, G., CarattiniRivera, S., DeM ayo, F., Bradley, A., Donehower, L., and Elledge, S. 2000. Chkl is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes. Dev. 14, 1448-1459.
    • Lubisch, W., Grandel, R., Braje, W., Subkowski, T., M ueller, R., Wemet, W., and Drescher, K. 2003. Preparation o f dibenzodiazepine derivatives and use as inhibitors o f poly (A D P-ribose) polymerase. In "WO 2003-EP192 20030110".
    • Lukas, C., Bartkova, J., Latella, L., Falck, J., M ailand, N., Schroeder, T., Sehested, M., Lukas, J., and Bartek, J. 2001. DNA damage-activated kinase Chk2 is independent o f proliferation or differentiation yet correlates with tissue biology. Cancer Res. 61,4990-4993.
    • Madani, H., Thompson, A. S., and Threadgill, M. D. 2002. An expedient synthesis o f 7- O-functionalised pyrrolo [2,1- c ][l,4 ] benzodiazepine-5,11-diones. Tetrahedron 58,8107-8111.
    • Makosza, M., and Kwast, E. 1995. Vicarious nucleophilic substitution o f hydrogen in nitroderivatives o f five-membered heteromatic compounds. Tetrahedron 51, 8339- 8354.
    • Malanga, M., and Althaus, F. R. 1994. Poly(Adp-Ribose) M olecules Formed During DNA-Repair in-Vivo. J. Biol. Chem. 269, 17691-17696.
    • Markwalder, J. A., Amone, M. R., Benfield, P. A., Boisclair, M., Burton, C. R., Chang, C. H., Cox, S. S., Czem iak, P. M., Dean, C. L., Doleniak, D., Grafstrom, R., Flarrison, B. A., Kaltenbach, R. F., Nugiel, D. A., Rossi, K. A., Sherk, S. R., Sisk, L. M., Stouten, P., Trainor, G. L., W orland, P., and Seitz, S. P. 2004. Synthesis and biological evaluation o f 1-aryl-4,5-dihydro-lFl-pyrazolo 3,4-d pyrimidin-4- one inhibitors o f cyclin-dependent kinases. J. Med. Chem 47, 5894-5911.
    • Meijer, L. 1995. Chemical inhibitors o f cyclin dependent kinases. Prog. Cell Cycle Res. 1, 351-363.
    • Meijer, L. 1996. Chemical inhibitors o f cyclin dependent kinases. Trends. Cell Biol. 6, 393-397.
    • Meijer, L., Thunnissen, A., W hite, A. W., Gamier, M., Nikolic, M., Tsai, L. H., Walter, J., Cleverley, K. E., Salinas, P. C., Wu, Y. Z., Biemat, J., Mandelkow, E. M., Kim, S. H., and Pettit, G. R. 2000. Inhibition o f cyclin-dependent kinases, GSK-3(3 and CK1 by hymenialdisine, a marine sponge constituent. Chem. Biol. 7, 51-63.
    • Morgan, D. O. 1995. Principles o f Cdk Regulation. Nature 374, 131-134.
    • Morgan, D. O., and Debondt, H. L. 1994. Protein-Kinase Regulation - Insights from Crystal-Structure Analysis. Curr. Opin. Cell Biol. 6, 239-246.
    • Moynahan, M. E., Chiu, J. W., Koller, B. H., and Jasin, M. 1999. B rcal controls homology-directed DNA repair. Mol. Cell. 4, 511-518.
    • Murray, A., and Hunt, T. 1993. "The Cell Cycle: an introduction," Freeman, W. H. and Company.
    • Murray, A. W. 2004. Recycling the cell cycle: cyclins revisited. Cell 116, 221-234.
    • Neidle, S., and Parkinson, G. 2002. Telom ere maintenance as a target for anticancer drug discovery. Nature Rev. Drug. Dis. 1, 383-393.
    • Newcomb, M., and Courtney, A. R. 1980. Reactions o f lithiostannanes with 6-halo-1- hexenes. J.Org.Chem. 45, 1707-1708.
    • Noble, M. E. M., and Endicott, J. A. 1999. Chemical inhibitors o f cyclin-dependent kinases: Insights into design from X-ray crystallographic studies. Pharmacol. Ther. 82, 269-278.
    • Noble, M. E. M., Endicott, J. A., Brown, N. R., and Johnson, L. N. 1997. The cyclin box fold: protein recognition in cell-cycle and transcription control. Trends Biochem. Sci. 22, 482-487.
    • Nugiel, D. A., Etzkom, A. M., Vidwans, A., Benfield, P. A., Boisclair, M., Burton, C. R., Cox, S., Czemiak, P. M., Doleniak, D., and Seitz, S. P. 2001. Indonopyrazoles as novel cyclin dependent kinase (CDK) inhibitors. J. Med. Chem. 44, 1334-1336.
    • Nurse, P. 1998. Yoshio Masui and cell cycle control, past, present and future. Biol. Cell. 90, 447-452.
    • Nurse, P., Masui, Y., and Hartwell, L. 1998. Understanding the cell cycle. Nat. Med. 4, 1103-1106.
    • Nyberg, K. A., Michelson, R. J., Putnam, C. W., and Weinert, T. A. 2002. Toward maintaining the genome: DNA damage and replication checkpoints. Annu. Rev. Genet. 36, 617-656.
    • O'Neill, T., Giarratani, L., Chen, P., Iyer, L., Lee, C. H., Bobiak, M., Kanai, F., Zhou, B. B., Chung, J. H., and Rathbun, G. A. 2002. Determination o f substrate motifs for human Chkl and hC dsl/C hk2 by the oriented peptide library approach. J. Biol. Chem. 277, 16102-16115.
    • Obaya, A. J., and Sedivy, J. M. 2002. Regulation o f cyclin-Cdk activity in mammalian cells. Cell. Mol. Life Sci. 59, 126-142.
    • Ogle, C. A., Martin, S. W., Dziobak, M. P., Urban, M. W., and Mendenhall, G. D. 1983. Decomposition rates, synthesis, and spectral properties o f a series o f alkyl hyponitrites. J.Med.Chem. 48, 3728-3733.
    • Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., Beach, D. H., and Harris, C. C. 1994.
    • Oliver, A. W., Arne, J. C., Roe, S. M., Good, V., de Murcia, G., and Pearl, L. H. 2004. Crystal structure o f the catalytic fragment o f murine poly (ADP-ribose) polymerase-2. N ucleic Acids Res. 32, 456-464.
    • PlanasSilva, M. D., and W einberg, R. A. 1997. The restriction point and control of cell proliferation. Curr. Opin. Cell B io l 9, 768-772.
    • Pommier, Y., Sordet, O., Rao, V. A., Zhang, H. L., and Kohn, K. W. 2005. Targeting Chk2 kinase: M olecular interaction maps and therapeutic rationale. Curr. Pharm. Design 11, 2855-2872.
    • Puodziunaite, B., Kosychova, L., Janciene, R., and Stumbreviciute, Z. 1997. 2,3-Dihydro1H-1,5-benzodiazepines: A conversion o f thiolactams to amidines. Mon. Chem. 128, 1275-1281.
    • Rahman, N., and Stratton, M. R. 1998. The genetics o f breast cancer susceptibility. Annu. Rev. Genet. 32, 95-121.
    • Raymond, E., Faivre, S., and Armand, J. P. 2000. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60, 15-23.
    • Rialet, V., and Meijer, L. 1991. A New Screening-Test for Antimitotic Compounds Using the Universal M Phase-Specific Protein-Kinase, P34cdc2 Cyclin B cdcl3, AffinityImmobilized on P I3 sucl-C oated M icrotitration Plates. Anti-cancer Res. 11, 1581- 1590.
    • Sausville, E. A. 2003. Cyclin-dependent kinase modulators studied at the NCI: preclinical and clinical studies. Curr. Med. Chem. - Anti Cancer Agents 3, 47-56.
    • Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., and Kunick, C. 1999. Paullones, a series o f cyclin-dependent kinase inhibitors: Synthesis, evaluation o f CDK 1/cyclin B inhibition, and in vitro antitumor activity. J. Med. Chem. 42, 2909-2919.
    • Schulze-Gahmen, U., Brandsen, J., Jones, H. D., Morgan, D. O., Meijer, L., Vesely, J., and Kim, S. H. 1995. M ultiple-M odes o f Ligand Recognition - Crystal-Structures o f Cyclin-Dependent Protein-Kinase-2 in Complex with Atp and two Inhibitors, Olomoucine and Isopentenyladenine. Protein-Struct. Fund. Genet. 22, 378-391.
    • Schulze-Osthoff, K., Los, M., and Baeuerie, P. A. 1995. Redox signalling by transcription factors NF-kappa B and AP-1 in lymphocytes. Biochem. Pharmacol. 50, 735.
    • Shieh, W. M„ Ame, J. C., W ilson, M. V., Wang, Z. Q„ Koh, D. W„ Jacobson, M. K., and Jacobson, E. L. 1998. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP- ribose polymers. J. Biol. Chem. 273, 30069-30072.
    • Sielecki, T. M., Boylan, J. F., Benfield, P. A., and Trainor, G. L. 2000. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation. Journal o f Medicinal Chemistry 43, 1-18.
    • Skalitzky, D. J., Marakovits, J. T., M aegley, K. A., Ekker, A., Yu, X. EL, Hostomsky, Z., Webber, S. E., Eastman, B. W., Almassy, R., Li, J., Curtin, N. J., Newell, D. R., Calvert, A. EL, Griffin, R. J., and Golding, B. T. 2003. Tricyclic benzimidazoles as potent poly (ADP-ribose) polym erase-1 inhibitors. J. Med. Chem. 46, 210-213.
    • Smith, S. 2001. The world according to PARP. Trends Biochem.Sci. 26, 174-179.
    • Smith, S., and de Lange, T. 2000. Tankyrase promotes telomere elongation in human cells. Curr. Biol. 10, 1299-1302.
    • Smith, S., Giriat, I., Schmitt, A., and de Lange, T. 1998. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484-1487.
    • Solomon, M. J., Glotzer, M., Lee, T. H., Philippe, M., and Kirschner, M. W. 1990. Cyclin Activation of P34cdc2. Cell 63, 1013-1024.
    • Solute, H. D., Vasquez, J., Long, A., Albert, S., and Brennan, M. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. J.Nat. Can. 51, 1409- 1416.
    • Sordet, O., Khan, Q., Kohn, K., and Pommier, Y. 2003. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents 3, 271-290.
    • Southan, G. J., and Szabo, C. 2003. Poly(ADP-ribose) polymerase inhibitors. Curr. Med. Chem. 10, 321-340.
    • Veeranna, G. J., Shetty, K. T., Amin, N., Grant, P., Albers, R. W., and Pant, H. C. 1996. Inhibition o f neuronal cyclin-dependent kinase-5 by staurosporine and purine analogs is independent o f activation by munc-18. Neurochem. Res. 21, 629-636.
    • Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donelladeana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., Leclerc, S., and Meijer, L. 1994. Inhibition of CyclinDependent Kinases by Purine Analogs. Eur. J. Biochem. 224, 771-786.
    • Webber, S. E., Canan-Koch, S. S., Tikhe, J., and Thoresen, L. H. 2000. Preparation o f 3,4-dihydropyrrolo[4,3,2-de]isoquinolin-5(lH)-ones and analogs as poly(ADPribose)polymerase inhibitors. In "200004204
    • Yao, S. L., Akhtar, A. J., McKenna, K. A., Bedi, G. C., Sidransky, D., Mabry, M., Ravi, R., Collector, M. I., Jones, R. J., Sharkis, S. J., Fuchs, E. J., and Bedi, A. 1996. Selective radiosensitization o f p53-deficient cells by caffeine-mediated activation o f p34(cdc2) kinase. Nat. Med. 2, 1140-1143.
  • No related research data.
  • No similar publications.
  • BioEntity Site Name
    2cpkProtein Data Bank
    2phkProtein Data Bank

Share - Bookmark

Cite this article